Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study.

IF 4.7 2区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Epidemiology Pub Date : 2024-03-12 DOI:10.1097/ede.0000000000001730

Rosa Sloot, Alexander Breskin, Lisandro D Colantonio, Andrew G Allmon, Ying Yu, Swati Sakhuja, Ligong Chen, Paul Muntner, M Alan Brookhart, Nafeesa Dhalwani

引用次数: 0

Abstract

Initiation of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9 mAb) for lipid-lowering following myocardial infarction (MI) is likely affected by patients' prognostic factors, potentially leading to bias when comparing real-world treatment effects.

查看原文本刊更多论文

使用阴性对照结果比较心肌梗死后 PCSK9 单克隆抗体治疗策略：目标试验模拟研究

心肌梗死（MI）后开始使用9型亚铁基转移酶/kexin单克隆抗体（PCSK9 mAb）降脂可能会受到患者预后因素的影响，从而可能导致在比较实际治疗效果时出现偏差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epidemiology 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.70

自引率

3.70%

发文量

177

审稿时长

6-12 weeks

期刊介绍： Epidemiology publishes original research from all fields of epidemiology. The journal also welcomes review articles and meta-analyses, novel hypotheses, descriptions and applications of new methods, and discussions of research theory or public health policy. We give special consideration to papers from developing countries.